Pharmafile Logo

Article: Market access in Brazil

All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient’s health.

In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

Read more on this article here: https://bit.ly/2qZ5HW1

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Research Partnership appoints new CEO

Research Partnership has appointed Gareth Phillips to take over as CEO

Infographic: Therapy Watch Hyperlipidaemia

Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study.

Article: The rise of the healthcare influencer

In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space.

How to elevate your communications testing with AI powered insights and analytics

Learn about a new behavioural science-led framework incorporating AI technologies that ensures you get a true reflection of how your communications materials are consumed and processed by customers

Infographic: Therapy Watch Psoriasis

Our PsO infographic offers an introduction to the real-world patient insights collected by our Therapy Watch PsO study.

Article: How behavioural economics can help you build better brand communications

For pharma marketers, accelerating brand performance means maximizing return on investment. Your campaigns need to trigger the right emotions, and the right actions, in your audience.

Article: From KOLs to KOIs – How to identify and engage the new healthcare influencers

Paul Reed and Basil Feilding investigate a new breed of KOLs with online influence and explain why pharma needs to join the conversation.

New syndicated patient reports –

Living with Uterine Fibroids and Endometriosis US 2022

Webcast: From perceptions to prescribing: Combining forces with next-generation tracking and benchmarking to accelerate brand performance

In this webcast we demonstrate RP and STEM's integrated approaches which gives clients the level of insights they need to accelerate brand performance.

Animation: Living With

The journey from the patient's perspective